Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: ENDPQ )

N/A UNCHANGED
Last Price Updated: 2:16 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ENDPQ

Bankrupt Generic Drugmaker Endo Secures Court Approval for $600M Opioid Epidemic Compensation Plan
Endo International (OTC: ENDPQ) has gained approval from U.S. Bankruptcy Court Judge James Garrity to initiate the solicitation of votes for its restructuring plan.  
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Generic Drugmaker Endo's Bankruptcy: Lenders Suggest $465M Payment To Settle Dispute With Federal Entities: Report
Endo International's (OTC: ENDPQ) lenders have reportedly proposed a fresh deal to settle with U.S. 
Via Benzinga
Rite Aid Once Top Drugstore Chain Lost Over 80% Of Stock Value In One Year: Opioid Litigation Takes Toll
Rite Aid Corp (NYSE: RAD) is reportedly on the brink of filing for bankruptcy amidst many lawsuits over its purported role in the opioid crisis to address its significant debt burden, which exceeds... 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Elon Musk Tells Employees Tesla Will Be 'Most Valuable Company On Earth, Sam Bankman-Fried Set To Enter Plea On Fraud Case, Twitter 'Should Feel Faster': Today's Top Stories
Reuters 
Via Benzinga
Venus Concept Taps Endo's Former CEO As New Chief Executive, Withdraws FY22 Guidance
Via Benzinga
Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug
Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower... 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.